Loading clinical trials...
Loading clinical trials...
A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Conditions
Interventions
TBX-2400
Locations
2
Croatia
University Hospital Centre Zagreb
Zagreb, Croatia
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Start Date
September 1, 2022
Primary Completion Date
August 28, 2024
Completion Date
October 28, 2024
Last Updated
May 3, 2022
NCT06859424
NCT06343805
NCT05123365
NCT07104799
NCT05037760
NCT06164561
Lead Sponsor
Taiga Biotechnologies, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions